| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Testing | 49 | 2024 | 1099 | 7.470 |
Why?
|
| Information Dissemination | 26 | 2024 | 200 | 7.160 |
Why?
|
| Genomics | 60 | 2024 | 1650 | 5.980 |
Why?
|
| Hallucinogens | 6 | 2025 | 51 | 4.840 |
Why?
|
| Genome, Human | 34 | 2024 | 1331 | 4.030 |
Why?
|
| Genetic Privacy | 15 | 2025 | 43 | 4.020 |
Why?
|
| Informed Consent | 31 | 2024 | 346 | 3.970 |
Why?
|
| Genetic Research | 16 | 2024 | 56 | 3.220 |
Why?
|
| Databases, Genetic | 18 | 2024 | 501 | 2.740 |
Why?
|
| Health Policy | 12 | 2025 | 233 | 2.720 |
Why?
|
| Biomedical Research | 18 | 2019 | 553 | 2.690 |
Why?
|
| Forensic Genetics | 5 | 2025 | 13 | 2.670 |
Why?
|
| Confidentiality | 14 | 2020 | 106 | 2.540 |
Why?
|
| Disclosure | 14 | 2019 | 152 | 2.270 |
Why?
|
| Parents | 18 | 2024 | 1079 | 2.220 |
Why?
|
| Public Opinion | 7 | 2025 | 61 | 2.190 |
Why?
|
| Sequence Analysis, DNA | 22 | 2019 | 1800 | 2.190 |
Why?
|
| Genealogy and Heraldry | 4 | 2025 | 9 | 2.120 |
Why?
|
| Research Subjects | 14 | 2023 | 54 | 2.070 |
Why?
|
| Direct-To-Consumer Screening and Testing | 6 | 2024 | 14 | 2.060 |
Why?
|
| Medical Informatics | 7 | 2019 | 110 | 1.910 |
Why?
|
| Athletes | 3 | 2024 | 73 | 1.900 |
Why?
|
| Humans | 219 | 2025 | 132064 | 1.870 |
Why?
|
| Physician's Role | 8 | 2020 | 169 | 1.810 |
Why?
|
| High-Throughput Nucleotide Sequencing | 13 | 2019 | 946 | 1.800 |
Why?
|
| Pedigree | 12 | 2025 | 1719 | 1.680 |
Why?
|
| Physician-Patient Relations | 13 | 2025 | 448 | 1.680 |
Why?
|
| Ethics, Medical | 10 | 2021 | 401 | 1.580 |
Why?
|
| Decision Making | 22 | 2024 | 700 | 1.570 |
Why?
|
| Whole Genome Sequencing | 10 | 2024 | 327 | 1.560 |
Why?
|
| Community Participation | 4 | 2019 | 42 | 1.540 |
Why?
|
| United States | 59 | 2025 | 11660 | 1.490 |
Why?
|
| Access to Information | 6 | 2022 | 45 | 1.430 |
Why?
|
| Neonatal Screening | 13 | 2024 | 192 | 1.380 |
Why?
|
| Genetics, Medical | 9 | 2019 | 121 | 1.370 |
Why?
|
| Genetics | 2 | 2020 | 24 | 1.320 |
Why?
|
| Genome-Wide Association Study | 10 | 2020 | 1829 | 1.280 |
Why?
|
| Privacy | 6 | 2022 | 28 | 1.230 |
Why?
|
| Ownership | 2 | 2019 | 35 | 1.210 |
Why?
|
| Physicians | 7 | 2022 | 640 | 1.150 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2024 | 3352 | 1.140 |
Why?
|
| DNA Fingerprinting | 2 | 2025 | 109 | 1.130 |
Why?
|
| Disease | 3 | 2020 | 127 | 1.110 |
Why?
|
| Genetic Counseling | 9 | 2024 | 245 | 1.110 |
Why?
|
| Attitude of Health Personnel | 9 | 2020 | 726 | 1.060 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 380 | 0.990 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 391 | 0.990 |
Why?
|
| Autopsy | 2 | 2016 | 117 | 0.980 |
Why?
|
| Research | 5 | 2016 | 265 | 0.960 |
Why?
|
| Truth Disclosure | 9 | 2019 | 105 | 0.930 |
Why?
|
| Quality Improvement | 2 | 2022 | 699 | 0.930 |
Why?
|
| Internet | 7 | 2025 | 406 | 0.930 |
Why?
|
| Exome | 12 | 2024 | 1088 | 0.910 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2025 | 20 | 0.900 |
Why?
|
| Health Insurance Portability and Accountability Act | 6 | 2020 | 21 | 0.890 |
Why?
|
| Touch | 1 | 2025 | 39 | 0.880 |
Why?
|
| Bioethics | 6 | 2020 | 74 | 0.880 |
Why?
|
| Physical Endurance | 1 | 2024 | 45 | 0.860 |
Why?
|
| Surveys and Questionnaires | 24 | 2025 | 3993 | 0.860 |
Why?
|
| Primary Health Care | 7 | 2018 | 793 | 0.840 |
Why?
|
| Ethics, Research | 7 | 2019 | 55 | 0.820 |
Why?
|
| Delivery of Health Care | 3 | 2025 | 698 | 0.820 |
Why?
|
| Human Genome Project | 2 | 2017 | 56 | 0.810 |
Why?
|
| Incidental Findings | 6 | 2018 | 130 | 0.810 |
Why?
|
| Controlled Substances | 1 | 2023 | 11 | 0.810 |
Why?
|
| Politics | 1 | 2024 | 62 | 0.810 |
Why?
|
| Law Enforcement | 3 | 2024 | 16 | 0.790 |
Why?
|
| Human Experimentation | 4 | 2023 | 35 | 0.790 |
Why?
|
| Leptin | 1 | 2024 | 219 | 0.780 |
Why?
|
| Patient Participation | 8 | 2023 | 240 | 0.780 |
Why?
|
| Energy Intake | 2 | 2024 | 493 | 0.780 |
Why?
|
| Adult | 52 | 2025 | 31571 | 0.780 |
Why?
|
| Marketing of Health Services | 3 | 2011 | 25 | 0.770 |
Why?
|
| Information Technology | 2 | 2019 | 9 | 0.760 |
Why?
|
| Hydrocortisone | 1 | 2023 | 226 | 0.740 |
Why?
|
| Consensus | 2 | 2024 | 649 | 0.740 |
Why?
|
| Research Personnel | 5 | 2024 | 136 | 0.740 |
Why?
|
| Health Information Exchange | 1 | 2022 | 10 | 0.730 |
Why?
|
| Bone and Bones | 1 | 2024 | 301 | 0.730 |
Why?
|
| Psychotherapy | 1 | 2025 | 246 | 0.730 |
Why?
|
| Health Records, Personal | 1 | 2022 | 21 | 0.730 |
Why?
|
| Patents as Topic | 3 | 2017 | 19 | 0.730 |
Why?
|
| Anti-Vaccination Movement | 1 | 2021 | 11 | 0.730 |
Why?
|
| Metagenome | 3 | 2012 | 146 | 0.720 |
Why?
|
| Precision Medicine | 5 | 2019 | 360 | 0.710 |
Why?
|
| Counseling | 3 | 2020 | 235 | 0.710 |
Why?
|
| Neoplasms | 12 | 2024 | 2952 | 0.710 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 155 | 0.710 |
Why?
|
| Consumer Health Information | 3 | 2010 | 29 | 0.710 |
Why?
|
| Models, Theoretical | 3 | 2021 | 391 | 0.700 |
Why?
|
| Family Relations | 1 | 2021 | 71 | 0.700 |
Why?
|
| Family | 9 | 2024 | 595 | 0.690 |
Why?
|
| Public Policy | 5 | 2017 | 54 | 0.690 |
Why?
|
| Ethics Consultation | 2 | 2016 | 28 | 0.690 |
Why?
|
| United States Food and Drug Administration | 6 | 2025 | 160 | 0.690 |
Why?
|
| Direct-to-Consumer Advertising | 1 | 2020 | 4 | 0.680 |
Why?
|
| Pediatricians | 1 | 2021 | 73 | 0.680 |
Why?
|
| Drug Industry | 3 | 2020 | 48 | 0.680 |
Why?
|
| Genotype | 5 | 2024 | 2697 | 0.670 |
Why?
|
| Betacoronavirus | 3 | 2020 | 299 | 0.660 |
Why?
|
| Alzheimer Disease | 2 | 2025 | 857 | 0.660 |
Why?
|
| Commerce | 2 | 2012 | 58 | 0.660 |
Why?
|
| Scholarly Communication | 1 | 2020 | 7 | 0.650 |
Why?
|
| Undocumented Immigrants | 1 | 2020 | 13 | 0.650 |
Why?
|
| Patient Preference | 4 | 2019 | 141 | 0.640 |
Why?
|
| DNA | 3 | 2010 | 1478 | 0.640 |
Why?
|
| Prescription Drugs | 1 | 2020 | 54 | 0.640 |
Why?
|
| Health Care Rationing | 1 | 2020 | 63 | 0.640 |
Why?
|
| Stakeholder Participation | 2 | 2019 | 32 | 0.630 |
Why?
|
| Occupational Stress | 1 | 2020 | 13 | 0.630 |
Why?
|
| Coroners and Medical Examiners | 2 | 2016 | 15 | 0.630 |
Why?
|
| Genetic Services | 1 | 2019 | 8 | 0.630 |
Why?
|
| Advisory Committees | 1 | 2020 | 151 | 0.620 |
Why?
|
| Firearms | 1 | 2020 | 58 | 0.610 |
Why?
|
| Male | 56 | 2025 | 64938 | 0.610 |
Why?
|
| Lysine Acetyltransferase 5 | 1 | 2019 | 6 | 0.610 |
Why?
|
| Multilingualism | 2 | 2018 | 43 | 0.610 |
Why?
|
| Liability, Legal | 3 | 2020 | 50 | 0.600 |
Why?
|
| Computer Security | 3 | 2022 | 28 | 0.600 |
Why?
|
| Physical Examination | 1 | 2020 | 165 | 0.600 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2024 | 899 | 0.590 |
Why?
|
| Databases as Topic | 1 | 2019 | 76 | 0.590 |
Why?
|
| Police | 1 | 2018 | 14 | 0.580 |
Why?
|
| Criminals | 1 | 2018 | 20 | 0.580 |
Why?
|
| Female | 59 | 2025 | 70664 | 0.580 |
Why?
|
| Criminal Law | 1 | 2018 | 14 | 0.570 |
Why?
|
| Empathy | 1 | 2018 | 64 | 0.570 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 73 | 0.560 |
Why?
|
| Military Personnel | 1 | 2020 | 203 | 0.560 |
Why?
|
| Cultural Competency | 1 | 2018 | 53 | 0.560 |
Why?
|
| Personal Autonomy | 7 | 2019 | 205 | 0.560 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 59 | 0.550 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2025 | 648 | 0.550 |
Why?
|
| Ethics Committees, Clinical | 2 | 2016 | 18 | 0.540 |
Why?
|
| Government Regulation | 4 | 2017 | 43 | 0.530 |
Why?
|
| Testosterone | 1 | 2023 | 611 | 0.530 |
Why?
|
| Language | 1 | 2018 | 224 | 0.520 |
Why?
|
| Internationality | 2 | 2021 | 133 | 0.520 |
Why?
|
| Social Media | 2 | 2018 | 120 | 0.510 |
Why?
|
| Mental Health | 1 | 2020 | 370 | 0.500 |
Why?
|
| Health Personnel | 3 | 2020 | 543 | 0.500 |
Why?
|
| Parenting | 2 | 2022 | 349 | 0.500 |
Why?
|
| Hospital Administrators | 1 | 2016 | 8 | 0.490 |
Why?
|
| Qualitative Research | 5 | 2025 | 664 | 0.480 |
Why?
|
| Insurance Selection Bias | 1 | 2015 | 1 | 0.460 |
Why?
|
| Cadaver | 3 | 2016 | 119 | 0.460 |
Why?
|
| Comprehension | 3 | 2018 | 81 | 0.460 |
Why?
|
| Insurance | 1 | 2015 | 8 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1300 | 0.440 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2017 | 456 | 0.440 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2014 | 36 | 0.440 |
Why?
|
| Employment | 1 | 2015 | 71 | 0.440 |
Why?
|
| Attitude | 5 | 2024 | 120 | 0.420 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1668 | 0.420 |
Why?
|
| Infant, Newborn | 19 | 2024 | 8542 | 0.400 |
Why?
|
| Anonymous Testing | 2 | 2013 | 2 | 0.400 |
Why?
|
| Quackery | 1 | 2012 | 2 | 0.400 |
Why?
|
| Technology Transfer | 1 | 2012 | 8 | 0.390 |
Why?
|
| Electronic Health Records | 4 | 2022 | 801 | 0.390 |
Why?
|
| Blood Preservation | 1 | 2012 | 30 | 0.390 |
Why?
|
| Specimen Handling | 3 | 2010 | 151 | 0.390 |
Why?
|
| Mental Recall | 1 | 2013 | 143 | 0.390 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 47 | 0.380 |
Why?
|
| Policy | 3 | 2023 | 37 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1305 | 0.370 |
Why?
|
| Mass Screening | 1 | 2018 | 828 | 0.370 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2014 | 159 | 0.370 |
Why?
|
| Risk Assessment | 11 | 2019 | 3731 | 0.370 |
Why?
|
| Cardiology | 4 | 2022 | 498 | 0.370 |
Why?
|
| Trust | 2 | 2025 | 83 | 0.360 |
Why?
|
| Middle Aged | 25 | 2025 | 28993 | 0.360 |
Why?
|
| Athletic Injuries | 1 | 2012 | 66 | 0.360 |
Why?
|
| Young Adult | 14 | 2024 | 9952 | 0.360 |
Why?
|
| Consanguinity | 1 | 2012 | 121 | 0.360 |
Why?
|
| Intellectual Property | 2 | 2022 | 9 | 0.350 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 2647 | 0.340 |
Why?
|
| Researcher-Subject Relations | 3 | 2012 | 6 | 0.340 |
Why?
|
| Oncologists | 2 | 2023 | 31 | 0.340 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 2089 | 0.330 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 249 | 0.330 |
Why?
|
| Psychometrics | 2 | 2024 | 687 | 0.330 |
Why?
|
| Cognitive Dysfunction | 2 | 2025 | 315 | 0.320 |
Why?
|
| Psoriasis | 2 | 2020 | 48 | 0.320 |
Why?
|
| Patient Rights | 1 | 2010 | 51 | 0.320 |
Why?
|
| Prenatal Diagnosis | 2 | 2014 | 631 | 0.320 |
Why?
|
| Communication | 5 | 2024 | 542 | 0.320 |
Why?
|
| Probiotics | 1 | 2012 | 226 | 0.320 |
Why?
|
| Health Status | 2 | 2017 | 407 | 0.310 |
Why?
|
| Public Health | 4 | 2020 | 281 | 0.310 |
Why?
|
| Students, Medical | 1 | 2014 | 363 | 0.310 |
Why?
|
| Huntington Disease | 1 | 2010 | 143 | 0.300 |
Why?
|
| Social Responsibility | 2 | 2019 | 84 | 0.300 |
Why?
|
| Adolescent | 17 | 2024 | 20542 | 0.300 |
Why?
|
| Federal Government | 1 | 2008 | 19 | 0.290 |
Why?
|
| Personal Health Services | 1 | 2008 | 1 | 0.290 |
Why?
|
| Databases, Nucleic Acid | 2 | 2019 | 73 | 0.290 |
Why?
|
| California | 2 | 2019 | 139 | 0.290 |
Why?
|
| Congenital Abnormalities | 1 | 2012 | 299 | 0.290 |
Why?
|
| Microbiota | 1 | 2013 | 434 | 0.280 |
Why?
|
| Lawyers | 2 | 2005 | 5 | 0.280 |
Why?
|
| Clinical Competence | 2 | 2014 | 1074 | 0.270 |
Why?
|
| Sequence Analysis | 2 | 2019 | 54 | 0.270 |
Why?
|
| Child | 21 | 2025 | 25763 | 0.270 |
Why?
|
| Harm Reduction | 2 | 2025 | 12 | 0.270 |
Why?
|
| Genetic Variation | 7 | 2019 | 1580 | 0.270 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 171 | 0.260 |
Why?
|
| Research Design | 4 | 2019 | 742 | 0.260 |
Why?
|
| Age of Onset | 4 | 2019 | 622 | 0.260 |
Why?
|
| Social Support | 1 | 2009 | 387 | 0.250 |
Why?
|
| Pilot Projects | 4 | 2025 | 1442 | 0.250 |
Why?
|
| Aged | 18 | 2024 | 21426 | 0.250 |
Why?
|
| Ethicists | 2 | 2016 | 46 | 0.240 |
Why?
|
| Deep Brain Stimulation | 2 | 2023 | 432 | 0.240 |
Why?
|
| Psilocybin | 1 | 2025 | 9 | 0.230 |
Why?
|
| Germ-Line Mutation | 2 | 2025 | 368 | 0.230 |
Why?
|
| National Human Genome Research Institute (U.S.) | 6 | 2018 | 19 | 0.230 |
Why?
|
| Ethics, Institutional | 1 | 2005 | 13 | 0.230 |
Why?
|
| Social Behavior | 2 | 2019 | 223 | 0.230 |
Why?
|
| Biomarkers | 2 | 2025 | 3403 | 0.230 |
Why?
|
| Biotechnology | 2 | 2016 | 59 | 0.230 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2025 | 23 | 0.230 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2017 | 135 | 0.230 |
Why?
|
| Crime | 1 | 2025 | 26 | 0.230 |
Why?
|
| Attitude to Health | 4 | 2019 | 262 | 0.220 |
Why?
|
| Death | 2 | 2016 | 79 | 0.220 |
Why?
|
| Emotions | 3 | 2024 | 367 | 0.220 |
Why?
|
| Ireland | 1 | 2024 | 32 | 0.220 |
Why?
|
| Consent Forms | 2 | 2016 | 22 | 0.220 |
Why?
|
| State Medicine | 1 | 2024 | 21 | 0.220 |
Why?
|
| Evidence-Based Practice | 2 | 2016 | 115 | 0.220 |
Why?
|
| Triiodothyronine | 1 | 2024 | 59 | 0.220 |
Why?
|
| Government | 1 | 2024 | 15 | 0.220 |
Why?
|
| Legislation, Medical | 2 | 2021 | 13 | 0.210 |
Why?
|
| Epigenomics | 1 | 2025 | 191 | 0.210 |
Why?
|
| Pandemics | 3 | 2020 | 1185 | 0.210 |
Why?
|
| Chromosome Mapping | 5 | 2019 | 1095 | 0.210 |
Why?
|
| Neurophysiology | 1 | 2023 | 19 | 0.210 |
Why?
|
| Consciousness | 1 | 2024 | 46 | 0.210 |
Why?
|
| Pediatrics | 2 | 2014 | 1211 | 0.210 |
Why?
|
| Spirituality | 1 | 2024 | 50 | 0.200 |
Why?
|
| Health Care Costs | 4 | 2019 | 415 | 0.200 |
Why?
|
| International Cooperation | 2 | 2017 | 167 | 0.200 |
Why?
|
| Delphi Technique | 1 | 2025 | 240 | 0.200 |
Why?
|
| Neurosciences | 2 | 2024 | 51 | 0.200 |
Why?
|
| Focus Groups | 1 | 2024 | 224 | 0.200 |
Why?
|
| Meningioma | 1 | 2025 | 139 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2025 | 232 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 5 | 2021 | 576 | 0.200 |
Why?
|
| Guidelines as Topic | 3 | 2014 | 198 | 0.190 |
Why?
|
| Meningeal Neoplasms | 1 | 2025 | 216 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 323 | 0.190 |
Why?
|
| Safety | 1 | 2023 | 216 | 0.190 |
Why?
|
| Caregivers | 2 | 2025 | 588 | 0.190 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 218 | 0.190 |
Why?
|
| Essential Tremor | 1 | 2023 | 94 | 0.180 |
Why?
|
| Translating | 2 | 2018 | 30 | 0.180 |
Why?
|
| Education, Graduate | 1 | 2002 | 19 | 0.180 |
Why?
|
| Humanities | 1 | 2002 | 16 | 0.180 |
Why?
|
| Exploratory Behavior | 1 | 2022 | 55 | 0.180 |
Why?
|
| Moral Obligations | 1 | 2022 | 76 | 0.180 |
Why?
|
| Certification | 1 | 2022 | 72 | 0.180 |
Why?
|
| Genes, BRCA2 | 2 | 2019 | 48 | 0.180 |
Why?
|
| Concept Formation | 1 | 2021 | 27 | 0.180 |
Why?
|
| Bone Density | 1 | 2024 | 367 | 0.180 |
Why?
|
| Genetic Carrier Screening | 2 | 2019 | 72 | 0.180 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 408 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2018 | 2850 | 0.180 |
Why?
|
| Texas | 5 | 2024 | 3627 | 0.180 |
Why?
|
| Economics, Medical | 1 | 2021 | 8 | 0.180 |
Why?
|
| Dystonia | 1 | 2023 | 172 | 0.180 |
Why?
|
| Seasons | 1 | 2023 | 327 | 0.170 |
Why?
|
| Ethics Committees, Research | 4 | 2010 | 32 | 0.170 |
Why?
|
| Trans-Activators | 1 | 2025 | 712 | 0.170 |
Why?
|
| Health Services Research | 1 | 2022 | 186 | 0.170 |
Why?
|
| Health | 2 | 2019 | 35 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 623 | 0.170 |
Why?
|
| RNA | 1 | 2024 | 552 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 803 | 0.170 |
Why?
|
| Dermatologists | 1 | 2020 | 5 | 0.170 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 113 | 0.170 |
Why?
|
| Depression, Postpartum | 1 | 2021 | 54 | 0.170 |
Why?
|
| Professional-Family Relations | 2 | 2018 | 96 | 0.170 |
Why?
|
| Child, Hospitalized | 1 | 2021 | 76 | 0.170 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 38 | 0.160 |
Why?
|
| Medical History Taking | 2 | 2018 | 114 | 0.160 |
Why?
|
| Space Flight | 1 | 2023 | 165 | 0.160 |
Why?
|
| Patients | 4 | 2018 | 129 | 0.160 |
Why?
|
| Motivation | 6 | 2022 | 330 | 0.160 |
Why?
|
| Nutritional Status | 1 | 2022 | 294 | 0.160 |
Why?
|
| Uncertainty | 2 | 2019 | 104 | 0.160 |
Why?
|
| Interleukin-12 | 1 | 2020 | 122 | 0.160 |
Why?
|
| United States Federal Trade Commission | 1 | 2019 | 2 | 0.160 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2019 | 5 | 0.160 |
Why?
|
| Clinical Decision-Making | 2 | 2022 | 306 | 0.160 |
Why?
|
| Mitochondrial Replacement Therapy | 1 | 2019 | 1 | 0.160 |
Why?
|
| Prevalence | 3 | 2023 | 2657 | 0.160 |
Why?
|
| Argonaute Proteins | 1 | 2019 | 31 | 0.160 |
Why?
|
| Implantable Neurostimulators | 1 | 2019 | 20 | 0.160 |
Why?
|
| Patient Education as Topic | 3 | 2013 | 465 | 0.160 |
Why?
|
| Eating | 1 | 2022 | 381 | 0.150 |
Why?
|
| Physicians, Primary Care | 2 | 2018 | 97 | 0.150 |
Why?
|
| Social Discrimination | 2 | 2019 | 5 | 0.150 |
Why?
|
| Insulin | 1 | 2024 | 1168 | 0.150 |
Why?
|
| North Carolina | 1 | 2019 | 67 | 0.150 |
Why?
|
| Energy Metabolism | 1 | 2024 | 785 | 0.150 |
Why?
|
| Tobacco Industry | 1 | 1999 | 7 | 0.150 |
Why?
|
| Linguistics | 1 | 2018 | 19 | 0.150 |
Why?
|
| Metagenomics | 1 | 2019 | 106 | 0.150 |
Why?
|
| History, 20th Century | 2 | 2017 | 385 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2022 | 423 | 0.150 |
Why?
|
| Fires | 1 | 1999 | 12 | 0.150 |
Why?
|
| Organizational Culture | 2 | 2016 | 102 | 0.150 |
Why?
|
| Triage | 1 | 2020 | 149 | 0.150 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 237 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 7107 | 0.150 |
Why?
|
| Biotinidase | 1 | 2018 | 2 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3760 | 0.150 |
Why?
|
| Neural Prostheses | 1 | 2018 | 4 | 0.150 |
Why?
|
| Communication Barriers | 1 | 2018 | 42 | 0.140 |
Why?
|
| Parent-Child Relations | 2 | 2021 | 253 | 0.140 |
Why?
|
| Risk Factors | 6 | 2019 | 10938 | 0.140 |
Why?
|
| Interviews as Topic | 2 | 2013 | 426 | 0.140 |
Why?
|
| Brain-Computer Interfaces | 1 | 2018 | 14 | 0.140 |
Why?
|
| Mutation | 4 | 2019 | 6226 | 0.140 |
Why?
|
| Legislation as Topic | 2 | 2020 | 5 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1500 | 0.140 |
Why?
|
| Information Services | 1 | 2017 | 22 | 0.140 |
Why?
|
| Device Removal | 1 | 2019 | 225 | 0.140 |
Why?
|
| Infant | 5 | 2024 | 13048 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 143 | 0.130 |
Why?
|
| Mitochondrial Diseases | 1 | 2019 | 147 | 0.130 |
Why?
|
| Loss of Function Mutation | 1 | 2018 | 159 | 0.130 |
Why?
|
| Classification | 1 | 2017 | 18 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 1160 | 0.130 |
Why?
|
| Cooperative Behavior | 2 | 2011 | 232 | 0.130 |
Why?
|
| Personal Satisfaction | 2 | 2018 | 106 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2019 | 209 | 0.130 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 504 | 0.130 |
Why?
|
| Ethical Theory | 1 | 2016 | 11 | 0.130 |
Why?
|
| Empirical Research | 1 | 2016 | 9 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 728 | 0.130 |
Why?
|
| Bioethical Issues | 1 | 2016 | 23 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 3009 | 0.130 |
Why?
|
| Algorithms | 2 | 2017 | 1718 | 0.130 |
Why?
|
| Ethical Analysis | 1 | 2016 | 48 | 0.130 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 669 | 0.120 |
Why?
|
| Minors | 1 | 2015 | 4 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2017 | 232 | 0.120 |
Why?
|
| Parkinson Disease | 1 | 2023 | 733 | 0.120 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 440 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2017 | 271 | 0.120 |
Why?
|
| Quality of Life | 2 | 2023 | 2158 | 0.120 |
Why?
|
| Parental Consent | 1 | 2015 | 22 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2018 | 306 | 0.120 |
Why?
|
| Patient Safety | 1 | 2020 | 439 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 662 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 213 | 0.110 |
Why?
|
| Child, Preschool | 6 | 2024 | 14734 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 295 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2025 | 2498 | 0.110 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 3682 | 0.110 |
Why?
|
| Supreme Court Decisions | 1 | 2014 | 17 | 0.110 |
Why?
|
| Research Report | 1 | 2015 | 71 | 0.110 |
Why?
|
| Behavioral Research | 1 | 2014 | 18 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2019 | 575 | 0.110 |
Why?
|
| Behavior | 1 | 2014 | 74 | 0.110 |
Why?
|
| Biological Specimen Banks | 2 | 2016 | 56 | 0.110 |
Why?
|
| Private Sector | 2 | 2016 | 27 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 1248 | 0.110 |
Why?
|
| Genes | 1 | 2014 | 313 | 0.100 |
Why?
|
| Survival Rate | 1 | 2019 | 2193 | 0.100 |
Why?
|
| State Government | 2 | 2015 | 30 | 0.100 |
Why?
|
| Veterans | 1 | 2025 | 1760 | 0.100 |
Why?
|
| Smoking | 1 | 1999 | 941 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2014 | 127 | 0.100 |
Why?
|
| Names | 1 | 2013 | 2 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 192 | 0.100 |
Why?
|
| Tissue Banks | 2 | 2012 | 30 | 0.100 |
Why?
|
| Genome | 1 | 2016 | 504 | 0.100 |
Why?
|
| Judgment | 1 | 2013 | 38 | 0.100 |
Why?
|
| Chromosomes, Human, Y | 1 | 2013 | 52 | 0.100 |
Why?
|
| Medical Tourism | 1 | 2012 | 2 | 0.100 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 755 | 0.100 |
Why?
|
| Medical Records | 1 | 2013 | 189 | 0.100 |
Why?
|
| Organizations | 1 | 2012 | 18 | 0.100 |
Why?
|
| Phenotype | 5 | 2018 | 4527 | 0.100 |
Why?
|
| Mass Media | 1 | 2012 | 28 | 0.100 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 430 | 0.100 |
Why?
|
| Laboratories | 1 | 2013 | 89 | 0.100 |
Why?
|
| Forecasting | 2 | 2019 | 372 | 0.090 |
Why?
|
| Patient Care | 1 | 2013 | 99 | 0.090 |
Why?
|
| Awareness | 1 | 2012 | 80 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2013 | 179 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 5412 | 0.090 |
Why?
|
| Incest | 1 | 2012 | 1 | 0.090 |
Why?
|
| Pharmacogenetics | 3 | 2021 | 200 | 0.090 |
Why?
|
| Social Welfare | 1 | 2012 | 7 | 0.090 |
Why?
|
| Mandatory Reporting | 1 | 2012 | 18 | 0.090 |
Why?
|
| HeLa Cells | 1 | 2013 | 731 | 0.090 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 1030 | 0.090 |
Why?
|
| Brain | 1 | 2023 | 3181 | 0.090 |
Why?
|
| Prognosis | 2 | 2019 | 5010 | 0.090 |
Why?
|
| Child Abuse, Sexual | 1 | 2012 | 34 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 2311 | 0.090 |
Why?
|
| United Kingdom | 2 | 2024 | 235 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2014 | 473 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2017 | 482 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2011 | 243 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 2057 | 0.090 |
Why?
|
| Device Approval | 1 | 2010 | 12 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2010 | 31 | 0.080 |
Why?
|
| Neurodegenerative Diseases | 1 | 2013 | 280 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 414 | 0.080 |
Why?
|
| Ethics, Professional | 1 | 2010 | 19 | 0.080 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 578 | 0.080 |
Why?
|
| Biological Therapy | 2 | 2020 | 25 | 0.080 |
Why?
|
| Persuasive Communication | 1 | 2010 | 12 | 0.080 |
Why?
|
| Directive Counseling | 1 | 2010 | 24 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 1989 | 0.080 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2015 | 1009 | 0.080 |
Why?
|
| Professional Autonomy | 2 | 2010 | 31 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2012 | 439 | 0.080 |
Why?
|
| Consumer Advocacy | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 508 | 0.080 |
Why?
|
| Ecosystem | 2 | 2024 | 107 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 230 | 0.070 |
Why?
|
| Social Change | 1 | 2008 | 15 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 632 | 0.070 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2010 | 239 | 0.070 |
Why?
|
| Patient Selection | 2 | 2018 | 732 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 3771 | 0.070 |
Why?
|
| Third-Party Consent | 1 | 2008 | 28 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 34 | 0.070 |
Why?
|
| Age Factors | 2 | 2019 | 2911 | 0.070 |
Why?
|
| Autistic Disorder | 1 | 2011 | 386 | 0.070 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 133 | 0.070 |
Why?
|
| Time Factors | 1 | 2018 | 6444 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2009 | 294 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 246 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2011 | 503 | 0.070 |
Why?
|
| Emergency Treatment | 1 | 2007 | 86 | 0.070 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 1859 | 0.060 |
Why?
|
| Publishing | 1 | 2008 | 106 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2010 | 852 | 0.060 |
Why?
|
| Medical Oncology | 2 | 2018 | 244 | 0.060 |
Why?
|
| Private Practice | 1 | 2005 | 22 | 0.060 |
Why?
|
| National Socialism | 1 | 2005 | 5 | 0.060 |
Why?
|
| Consultants | 1 | 2005 | 11 | 0.060 |
Why?
|
| Beneficence | 1 | 2005 | 84 | 0.060 |
Why?
|
| Hospital Administration | 1 | 2005 | 25 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2005 | 67 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1443 | 0.050 |
Why?
|
| Professional Competence | 1 | 2005 | 95 | 0.050 |
Why?
|
| Biomedical Technology | 1 | 2024 | 36 | 0.050 |
Why?
|
| Epilepsy | 1 | 2011 | 889 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2022 | 6570 | 0.050 |
Why?
|
| Ovarian Neoplasms | 2 | 2019 | 462 | 0.050 |
Why?
|
| Risk | 2 | 2016 | 761 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 309 | 0.050 |
Why?
|
| Probability | 1 | 2024 | 322 | 0.050 |
Why?
|
| Amyloid | 1 | 2024 | 69 | 0.050 |
Why?
|
| HIV Infections | 1 | 2015 | 2047 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 333 | 0.050 |
Why?
|
| Models, Economic | 2 | 2000 | 61 | 0.050 |
Why?
|
| Germ Cells | 1 | 2024 | 204 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1411 | 0.050 |
Why?
|
| Vulnerable Populations | 1 | 2005 | 147 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2025 | 234 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 5168 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 767 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 41 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 229 | 0.050 |
Why?
|
| Family Health | 1 | 2022 | 256 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2398 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 1017 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 308 | 0.050 |
Why?
|
| Data Collection | 2 | 2014 | 391 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 45 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3412 | 0.040 |
Why?
|
| Depression | 2 | 2021 | 1339 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2554 | 0.040 |
Why?
|
| Interdisciplinary Research | 1 | 2021 | 10 | 0.040 |
Why?
|
| Genes, Recessive | 2 | 2013 | 193 | 0.040 |
Why?
|
| Universities | 1 | 2002 | 129 | 0.040 |
Why?
|
| Economics, Pharmaceutical | 1 | 2000 | 6 | 0.040 |
Why?
|
| Health Behavior | 2 | 2017 | 399 | 0.040 |
Why?
|
| Ustekinumab | 1 | 2020 | 3 | 0.040 |
Why?
|
| Goals | 2 | 2016 | 133 | 0.040 |
Why?
|
| Computational Biology | 3 | 2012 | 875 | 0.040 |
Why?
|
| Base Sequence | 2 | 2017 | 2900 | 0.040 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2020 | 6 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2024 | 537 | 0.040 |
Why?
|
| Arthritis | 1 | 2000 | 86 | 0.040 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 40 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2007 | 1168 | 0.040 |
Why?
|
| Surgeons | 1 | 2024 | 286 | 0.040 |
Why?
|
| Learning | 1 | 2022 | 370 | 0.040 |
Why?
|
| Government Agencies | 1 | 1999 | 12 | 0.040 |
Why?
|
| Drug Approval | 1 | 2019 | 46 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1230 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2000 | 282 | 0.040 |
Why?
|
| Organizational Policy | 1 | 1999 | 54 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2019 | 240 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 305 | 0.040 |
Why?
|
| Duty to Recontact | 1 | 2018 | 2 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 436 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 372 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 215 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2018 | 143 | 0.040 |
Why?
|
| Intention | 1 | 2018 | 101 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2019 | 373 | 0.030 |
Why?
|
| Software | 2 | 2016 | 731 | 0.030 |
Why?
|
| Siblings | 1 | 2019 | 202 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 2018 | 104 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 242 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 372 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 86 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 60 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 956 | 0.030 |
Why?
|
| Hospitals | 1 | 2020 | 439 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2018 | 247 | 0.030 |
Why?
|
| American Heart Association | 1 | 2018 | 309 | 0.030 |
Why?
|
| Face | 1 | 2018 | 188 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 713 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 241 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1127 | 0.030 |
Why?
|
| Population Groups | 1 | 2016 | 31 | 0.030 |
Why?
|
| Perception | 1 | 2018 | 237 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2016 | 62 | 0.030 |
Why?
|
| Alleles | 2 | 2013 | 1683 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 222 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 730 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 518 | 0.030 |
Why?
|
| Genomic Structural Variation | 1 | 2017 | 92 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 679 | 0.030 |
Why?
|
| Down Syndrome | 1 | 2018 | 231 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1284 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2015 | 53 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1360 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1174 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2015 | 108 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 1560 | 0.030 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 95 | 0.030 |
Why?
|
| Reproductive Health Services | 1 | 2014 | 19 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 485 | 0.030 |
Why?
|
| Inservice Training | 1 | 2014 | 57 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2017 | 335 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 123 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2017 | 569 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2019 | 2679 | 0.020 |
Why?
|
| Penetrance | 1 | 2013 | 113 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2013 | 250 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 144 | 0.020 |
Why?
|
| Genes, rRNA | 1 | 2012 | 18 | 0.020 |
Why?
|
| Cognition | 1 | 2018 | 810 | 0.020 |
Why?
|
| Seizures | 1 | 2018 | 892 | 0.020 |
Why?
|
| Anxiety | 1 | 2019 | 991 | 0.020 |
Why?
|
| Gene Order | 1 | 2012 | 82 | 0.020 |
Why?
|
| Factor V | 1 | 2012 | 15 | 0.020 |
Why?
|
| Klinefelter Syndrome | 1 | 2012 | 21 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 236 | 0.020 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2012 | 62 | 0.020 |
Why?
|
| Inheritance Patterns | 1 | 2012 | 130 | 0.020 |
Why?
|
| Turner Syndrome | 1 | 2012 | 45 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2014 | 359 | 0.020 |
Why?
|
| Presumed Consent | 1 | 2011 | 4 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2011 | 25 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1596 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2010 | 21 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 394 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2010 | 46 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2010 | 59 | 0.020 |
Why?
|
| Homozygote | 1 | 2012 | 547 | 0.020 |
Why?
|
| Academies and Institutes | 1 | 2010 | 88 | 0.020 |
Why?
|
| Phylogeny | 1 | 2012 | 763 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1997 | 1061 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2011 | 177 | 0.020 |
Why?
|
| Bias | 1 | 2010 | 143 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 144 | 0.020 |
Why?
|
| Organ Preservation Solutions | 1 | 2009 | 19 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 777 | 0.020 |
Why?
|
| Quality Control | 1 | 2009 | 123 | 0.020 |
Why?
|
| Curriculum | 1 | 2014 | 767 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2011 | 180 | 0.020 |
Why?
|
| Individuality | 1 | 2008 | 37 | 0.020 |
Why?
|
| Ethics, Clinical | 1 | 2007 | 77 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2011 | 523 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2008 | 615 | 0.020 |
Why?
|
| Health Promotion | 1 | 2010 | 399 | 0.020 |
Why?
|
| Critical Illness | 1 | 2011 | 618 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2010 | 933 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 1045 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2139 | 0.010 |
Why?
|
| Pregnancy | 1 | 2015 | 7554 | 0.010 |
Why?
|
| Celecoxib | 1 | 2000 | 32 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2000 | 285 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2000 | 332 | 0.010 |
Why?
|
| Value of Life | 1 | 1997 | 9 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 1997 | 141 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2000 | 13000 | 0.010 |
Why?
|